The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab

Br J Haematol. 2023 Apr;201(1):e1-e4. doi: 10.1111/bjh.18662. Epub 2023 Jan 19.

Authors

Michela Sica¹, Federica Barone¹, Caterina Nannelli¹, Patrizia Ricci², Luana Marano³, Maria De Angioletti^{1

4}, Eros Di Bona⁵, Antonio M Risitano^{2

3}, Rosario Notaro^{1

6}

Affiliations

¹ Core Research Laboratory, Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Florence, Italy.
² Federico II University of Naples, Naples, Italy.
³ AORN Moscati, Avellino, Italy.
⁴ ICCOM-National Council of Research, Florence, Italy.
⁵ Onco-Haematology, AULSS 7 Pedemontana, Bassano del Grappa, Italy.
⁶ Haematology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.

PMID: 36660816
DOI: 10.1111/bjh.18662

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Erythrocytes*
Hemoglobinuria, Paroxysmal* / drug therapy
Hemolysis
Humans

Substances

ravulizumab
eculizumab
Antibodies, Monoclonal, Humanized